Pembrolizumab-associated chronic rhinosinusitis: A new endotype and management considerations.

Autor: Standiford TC; Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head & Neck Surgery, University of California, San Francisco, California, USA., Patel NN; Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head & Neck Surgery, University of California, San Francisco, California, USA., Singh A; Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head & Neck Surgery, University of California, San Francisco, California, USA., Gochman G; Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head & Neck Surgery, University of California, San Francisco, California, USA., Jamie Wu T; Department of Otolaryngology-Head & Neck Surgery, University of California, Los Angeles, California, USA., Daud AI; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA., Goldberg AN; Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head & Neck Surgery, University of California, San Francisco, California, USA.
Jazyk: angličtina
Zdroj: International forum of allergy & rhinology [Int Forum Allergy Rhinol] 2023 Dec; Vol. 13 (12), pp. 2248-2251. Date of Electronic Publication: 2023 Jul 05.
DOI: 10.1002/alr.23213
Abstrakt: Key Points: Patients treated with pembrolizumab experience an increase in paranasal sinus inflammation Use of topical triamcinolone in carboxymethylcellulose is a treatment option for such patients.
(© 2023 ARS-AAOA, LLC.)
Databáze: MEDLINE
Externí odkaz: